Related Experiment Video
Updated: Jul 20, 2026
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
Published on: May 27, 2015
KIT mutations in mastocytosis and their potential as therapeutic targets
1Stanford Cancer Center, Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2327B, Stanford, CA 94305-5821, USA. jason.gotlib@stanford.edu
Abstract:
Deregulation of the KIT receptor TK by the prevalent activation loop mutation D816V has served as a focal point in therapeutic strategies aimed curbing neoplastic mast cell growth. Perhaps the most important development in this era of targeted therapy, and certainly relevant to KIT-driven diseases like mastocytosis, is the realization that small molecule inhibitors with varied chemical structure (eg, PKC412, dasatinib, AP23464) can circumvent the resistance of TKs to first-generation agents such as imatinib. Genuine opportunity now exists to effectively treat mastocytosis, and the arsenal consists of several orally bioavailable drugs with promising preclinical activity against D816V and other KIT mutants that promote mast cell growth. Because KIT mutations may not act as fully transforming oncogenic events in SM, it is prudent to evaluate combinations of TK inhibitors with drugs with activity in mast cell disease, such as cladribine, interferon-alpha, and corticosteroids. The identification of novel "drug-able" targets within mast cells should aid in the development of complementary therapies that promote enhanced cytotoxicity of mast cells through blockade of nonredundant signaling pathways. In addition, the generation of murine models that recapitulate human mastocytosis should accelerate preclinical testing of novel agents.
Insights
New targeted therapies, including small molecule inhibitors, show promise for treating mast cell growth driven by KIT mutations like D816V. Combination therapies may offer enhanced efficacy for mastocytosis.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- The KIT receptor tyrosine kinase (TK) is frequently deregulated in neoplastic mast cell growth, particularly by the D816V mutation.
- Imatinib resistance in KIT-driven diseases necessitates the development of alternative therapeutic strategies.
Purpose of the Study:
- To review the therapeutic landscape for KIT-driven mast cell disorders.
- To highlight the potential of novel small molecule inhibitors and combination therapies.
Main Methods:
- Review of preclinical data and clinical developments in KIT-targeted therapies.
- Evaluation of emerging small molecule inhibitors (e.g., PKC412, dasatinib, AP23464) against KIT mutants.
- Consideration of combination strategies with existing mast cell disease treatments (e.g., cladribine, interferon-alpha, corticosteroids).
Main Results:
- Several orally bioavailable small molecule inhibitors demonstrate preclinical activity against D816V and other KIT mutants.
- These agents can overcome resistance mechanisms associated with first-generation TK inhibitors.
- Combinations of TK inhibitors with other agents show potential for enhanced mast cell cytotoxicity.
Conclusions:
- A new era of targeted therapy offers genuine opportunities for effectively treating mastocytosis.
- Combination therapies targeting KIT and other pathways are crucial for managing mast cell disorders.
- Development of novel drug targets and preclinical models will accelerate therapeutic advancements.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
02:23Abnormal Proliferation